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In the early 1990s the concept of transcatheter aortic 
valve implantation (TAVI) appeared challenging and 
totally unrealistic. It was a true “resurrection” for Cribier 
and his whole team1 performing the first TAVI in an 
inoperable patient in 2002, using a transeptal antegrade 
approach and balloon-expandable aortic valve prosthesis. 
Since then TAVI has been performed in more than 50000 
patients worldwide. TAVI is currently indicated in 
patients with severe symptomatic aortic stenosis (AS) and 
acceptable life expectancy who are not suitable for aortic 
valve replacement (AVR) (indication class IB) or as an 
alternative to aortic valve replacement (AVR) in 
selected high-risk operable patients (class IIB), according 
to the “Heart Team” assessment.2
The TAVI Heart Team comprised of clinical 
cardiologists, interventionalists, surgeons, anaesthetists
and imaging specialists with expertise in the treatment of 
valve disease, selects patients suitable for TAVI taking 
into account advantages and disadvantages of both AVR 
and TAVI. A logistic EuroSCORE  ORJLVWLF
EuroSCORE I tends to overestimate observed mortality 
risk by a factor of 2 to 3 and a newly updated logistic 
EuroSCORE II is currently available in clinical practice) 
or a Society of Thoracic Surgeons (STS) score >10% 
are suggested as indications for TAVI therapy.3 Recent 
publications have identified a number of baseline 
variables independently associated with mortality or poor 
outcome in patients undergoing TAVI (low body mass, 
functional status, left ventricular dysfunction, NT-
proBNP, prior stroke, diabetes, chronic kidney disease, 
anemia, severe tricuspid and mitral regurgitation, 
porcelain aorta or history of chest radiation) which could 
be integrated into new scoring systems to quantify and 
predict the prognosis of TAVI both in the immediate and 
in the long term (Table 1).4 Apart from certain absolute 
and relative contraindications for TAVI (Table 2)2 a 
number of subgroups require more precise evaluation, for 
example transcatheter ‘valve in a valve’ appears as an 
attractive alternative in bioprosthesis failure with more 
than 100 successful TAV-in-surgical aortic valve 
procedures already been performed.5,6 Several successful 
case reports document stenotic bicuspid aortic valves 
been treated with TAVI and according to a German 
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registry, 16% of patients with intermediate risk of surgery 
for AS have chosen TAVI as a therapeutic regimen.7
The most important aspect of anatomical screening 
involves assessment of arterial vasculature and aortic 
valve complex to guide access route (transfemoral, 
transapical, subclavian or direct aortic) and transcatheter 
valve size.3 Peripheral contrast angiography is practical 
and associated with relatively lower costs and lower 
radiation or contrast exposure compared with multislice 
computed tomography (MSCT), which provides more 
precise information regarding vessel size, tortuosity and 
calcific burden. Typically the femoral artery is used for 
vascular access and vascular injuries are treated “on the 
way out” by percutaneous transluminal angioplasty, stent 
implantation or surgery. 
The aortic valve complex (left ventricular outflow 
tract, aortic annulus, sinus of Valsalva, sinotubular 
junction and ascending aorta) can be measured by 
different imaging modalities including echocardiography 
(transthoracic, transesophageal or 3D), aortography, 
MSCT and magnetic resonance imaging. Due to a non-
circular shape of the aortic valve annulus it is difficult to 
find the proper sizing of the transcatheter aortic 
bioprostheses and routinely the implanted valves are 
oversized to limit aortic regurgitation and obtain 
procedural success.7 Currently two valve models are 
available: the Edwards SAPIEN valve and the Medtronic 
CoreValve. The Edwards SAPIEN valve consists of tri-
leaflet bovine-pericardium valve mounted on a 
balloon-expandable stainless steel stent, is available in 
four sizes (20, 23, 26 and 29 mm) and can be implanted 
in native annuli with diameters of 16 to 27 mm. The 
CoreValve has an autoexpandable nitinol stent containing 
a porcine pericardial valve, is available in three sizes (26, 
29 and 31 mm) and can be implanted in native annuli 
ranging from 20 to 29 mm.1,3 
Optimal management of patients undergoing TAVI 
includes resolving a vast variety of issues and constantly 
improving valves and delivering systems. According to 
published case series, up to three quarters of TAVI 
patients have coronary artery disease and percutaneous 
coronary intervention (PCI) is reported in up to 44% of 
them, safely performed in addition to TAVI either as a 
staged or a concomitant intervention.8 Stroke has been 
highlighted as an important problem after TAVI: most 
periprocedural and postprocedural strokes are of embolic 
origin (new cerebral lesions have been reported in 58 to 
91% of patients undergoing TAVI)9 and studies are 
ongoing to establish the proper therapeutic regimen 
including embolic protection devices and dual antiplatelet 
therapy. Complete heart block is frequently reported after 
TAVI because transcatheter valves are implanted lower 
into the left ventricular outflow tract against the 
interventricular septum. Treating TAVI patients with 
improved delivery systems will ameliorate valve 
positioning and decrease the incidence of this 
complication as well; rate of new pacemaker 
implantation reaches 9-36% with the CoreValve and 3-
12% with the Edwards device.10
Several large registries have been published showing 
excellent short- and mid- term results after TAVI using 
both the transfemoral (TF) and the transapical (TA) 
access route. The SOURCE registry enrolled 1038 
patients at 32 European centers, treated with an Edwards 
SAPIEN valve either by TF (n=463) or TA (n=575) 
approach; procedural success was 95.2% and 92.7%, 
30-day mortality was 6.3% and 10.3%, and 1-year 
survival was 72.1% and 81.1%, respectively.11 The 
ADVANCE registry included 1015 patients with mean 
logistic EuroSCORE 19.2% and measured 
cardiovascular/all-cause mortality at 30 days (3.4/ 4.5%), 
6 months (8.4 / 12.8%) and 1 year (11.8 / 17.9%) 
respectively.12 In 2011 four mixed national registries 
showed 1-year survival rate ranging between 71.9 to 
81.6% and 2-year survival rate 73.7%7 and the recent 
FRANC 2 registry reported procedural success rate 
96.9% and 1-year survival 76%.13
While registries contribute to better appraisal of 
patient screening, improvements in technical modalities 
and better management of complications in the ‘real 
world’ of TAVI, more rigorous assessments are available 
from the first multicentre, randomized clinical 
PARTNER Trial (Placement of Aortic Transcatheter 
Valves). At first, a total of 358 patients with inoperable 
aortic stenosis underwent randomization (TAVI versus 
standard therapy, including balloon aortic valvuloplasty) 
and it was found that at 1 year, TAVI resulted in reduced 
rates of death from any cause (30.7% in the TAVI group 
vs 50.7% in standard therapy, P<0.001), composite end 
point of death or repeat hospitalization and cardiac 
symptoms, despite a higher incidence of major strokes 
and vascular events.14 Survival advantage associated with 
TAVI remained significant at 2 years of follow-up; rate 
of deaths 43.3% in the TAVI group and 68% in the 
standard therapy group (P<0.001) – cardiac mortality 
31% and 62.4% respectively (P<0.001). Moreover, in the 
TAVI group rehospitalizations were less, functional 
status and echocardiographic findings remained improved 
at 2 years.15
The PARTNER cohort A compared TAVI with AVR 
and met its non-inferiority endpoint; the all-cause 
mortality was 3.4% in the TAVI group and 6.5% in the 
AVR group at 30 days (P=0.07) and, at 1 year 24.2% 
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versus 26.8% respectively (P=0.44). At 30 days major 
vascular complications were significantly more frequent 
with TAVI (11% versus 3.2%, P<0.001), while major 
bleeding (9.3% versus 19.5%, P<0.001) and new-onset 
atrial fibrillation (8.6% versus 16%) were more frequent 
in AVR.16 Most recently, a 2-year follow up of patients in 
the PARTNER Trial has been published supporting TAVI 
as an alternative to AVR in high-risk patients.  It was 
found that all-cause mortality (33.9% in the TAVI group, 
35% in the AVR group, P=0.78) and cardiovascular 
mortality (21.4% in the TAVI group, 20.5% in the AVR 
group, P=0.80) at 2-years were similar in both groups and 
most importantly, the frequency of all strokes during 
follow up did not differ either (P=0.52). Both treatments 
were found similar with respect to mortality, reduction in 
symptoms and improved valve hemodynamics but 
paravalvular regurgitation was more frequent after TAVI 
(P<0.001) and was associated with increased late 
mortality (P<0.001).17   
Subanalysis of the PARTNET cohort A regarding 
health status and quality of life in high-risk patients with 
severe AS demonstrated substantially improved health 
status with TAVI at 1 month (via the TF but not the TA 
route) and similar findings for both TAVI/AVR at 6 and 
12 months.18 TAVI has been shown to be superior to 
standard medical therapy resulting in ameliorated quality 
of life with mean cost $42806 for the initial procedure 
and $78542 for the whole hospitalization, but reduced 
hospitalization rates through the first year of follow-up
make TAVI an economically attractive strategy.19
Although 12-month costs and quality-adjusted life-years 
(QALY) were found similar for TAVI and AVR in the 
overall population of PARTNER cohort A, total 12-
month costs were slightly lower and QALYs were higher 
for patients undergoing TAVI via the TF route (results for 
the TA cohort were economically unfavorable);
nevertheless, additional studies are needed to establish 
TAVI a cost-effective therapeutic regimen.20 Finally, the 
PARTNER Stroke Substudy analyzed all neurologic 
events (transient ischemic attacks and strokes) of patients 
treated with either TAVI or AVR and concluded that 
neurologic complications occurred more frequently after 
TAVI in the early phase but thereafter, the risk was 
influenced by patient- and disease-related factors (e.g. 
history of recent stroke or transient ischemic attack, 
advanced functional disability).21
Table 1. Predictors of long-term mortality after 
TAVI4
Advanced age
Smoking
Logistic EuroSCORE
STS Score
Calcium Score
Baseline anemia
Baseline renal failure, acute kidney injury
Pulmonary hypertension
COPD
Liver disease
Prior stroke
Major vascular complication
Myocardial injury
Systematic inflammatory response syndrome
Learning curve, early experience with TAVI 
COPD = chronic obstructive pulmonary disease; TAVI = 
transcatheter aortic valve implantation
Table 2. Contraindications for transcatheter aortic 
valve implantation2
Absolute 
contraindications
Life expectancy < 1 year
Major comorbidities resulting in minor 
improvement of quality of life
Disease of other valves with need for 
surgical treatment
Inadequate annulus size (< 18mm/ >29 mm)
Thrombus in LV
Active endocarditis
Elevated risk of coronary ostium 
obstruction due to anatomical 
characteristics
Plaques with mobile thrombi in the 
ascending aorta or arch
For transfemoral/subclavian approach: 
inadequate vascular access (vessel size, 
calcification, tortuosity) 
Relative 
contraindications
Bicuspid or non calcified valves
CAD requiring revascularization
Hemodynamic instability
LV ejection  fraction <20%
For transapical approach: severe 
pulmonary disease, LV apex not accessible
CAD = coronary artery disease; LV = left ventric-le(-ular)
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